Gossamer Bio Inc., a clinical biopharmaceutical company, has entered into a global collaboration agreement with the Chiesi Group to jointly develop seralutinib for the treatment of pulmonary arterial hypertension (PAH). This partnership aims to advance seralutinib as a potential first-in-class treatment option, with the companies focusing on Functional Class II and III PAH patients. The collaboration is currently centered on the ongoing Phase 3 PROSERA Study, which recently completed enrollment. This study is a critical step in evaluating the efficacy of seralutinib and is expected to yield topline results in February 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.